Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO (ICONE)
Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Transfusion Related Complication
About this trial
This is an interventional treatment trial for Cardiogenic Shock focused on measuring ECMO, ECLS, Refractory cardiogenic shock, Transfusion, ScVO2, Outcome
Eligibility Criteria
Inclusion Criteria: Age of 18 and older, supported by peripheral VA-ECMO for cardiogenic shock Life expentency >90 days Central venous line available ScVO2 measurement Exclusion Criteria: Pregnancy, Lack of health insurance, Opposition to blood transfusion, Known congenital hemoglobin disease or disorder, Metabolic alcaloosis with pH>7.8, eCPR, Legally incapacitated adults
Sites / Locations
- Service d'Anesthésie-Réanimation CCV Hôpital Cardiologique Centre Hospitalier et Universitaire de Lille
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Individulised transfusion strategy group
Conventionnal transfusion strategy group
Patients will recieve red blood cells transfusion in case of a drop of ScVO2 <65% after an assessment for the optimisation of SaO2 normalisation (SaO2>94%), volume optimisation, ECMO output increase, Fever (body temperature 38°3 C°), Anxiety and Pain
Transfusion will be performed in case of a hemoglobin drop <9 g/dL